ACCESS Newswire
Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method
📈
AI Sentiment
Highly Positive
9/10
- Home
- RGNT
RGNT
Regentis Biomaterials Ltd. Ordinary Shares
as of 01-22-2026 3:59pm EST
$7.20
$0.05
-0.69%
| Founded: | 2004 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 36.9M | IPO Year: | 2025 |
| Target Price: | N/A | AVG Volume (30 days): | 40.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.75 - $8.35 | Next Earning Date: | 02-08-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Regentis Biomaterials Ltd. Ordinary Shares News
RGNT Breaking Stock News: Dive into RGNT Ticker-Specific Updates for Smart Investing
Compare RGNT vs Leading Stocks
See how RGNT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RGNT Regentis Biomaterials Ltd. Ordinary Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.